Added to YB: 2026-03-31
Pitch date: 2026-02-06
GRCE [bullish]
Grace Therapeutics, Inc.
+21.45%
current return
Author Info
No bio for this author
Company Info
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Market Cap
$72.3M
Pitch Price
$3.59
Price Target
10.80 (+131%)
Dividend
N/A
EV/EBITDA
-4.77
P/E
-12.23
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Grace Therapeutics, Inc. - $GRCE
GRCE: Microcap biotech w/ single late-stage asset GTx-104, IV nimodipine for aSAH (deadliest stroke, 40k US cases). Only FDA-approved therapy, Class I recommendation. Ph3 STRIVE-ON met primary endpoint: no increase in hypotension vs oral; 54% achieved ≥95% dose vs 8% oral; better functional outcomes (74% vs 48% mRS 0-2). NDA accepted, PDUFA Apr 23 '26. Orphan exclusivity, patents to 2040s. Peak sales est $126M, implied EV $283M vs current $65-70M EV = 3x upside. Funded through commercialization. 90%+ PoS.
Read full article (16 min)